World's Best Scientists 2026 revealed!
Hiroji Iwata

Hiroji Iwata

D-Index & Metrics

Medicine

D-Index
96
Citations
61708
World Ranking
9460
National Ranking
255

Overview

Hiroji Iwata is affiliated with the Aichi Cancer Center in Japan and primarily focuses on research in medicine, with significant contributions in oncology. Their work spans across several subfields including oncology, pulmonary and respiratory medicine, cancer research, genetics, and molecular biology. The scientist's main research topics include advanced breast cancer therapies, HER2/EGFR in cancer research, breast cancer treatment studies, cancer treatment and pharmacology, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, and monoclonal and polyclonal antibodies research.

Their publication record includes significant papers related to breast cancer and cancer therapies. Notable recent papers include:

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, 2020, The Lancet
  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial, 2020, The Lancet
  • Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer, 2022, New England Journal of Medicine
  • Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study, 2020, Journal of Clinical Oncology
  • Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial, 2022, The Lancet

Hiroji Iwata frequently collaborates with other researchers, including:

  • Norikazu Masuda
  • Masataka Sawaki
  • Hope S. Rugo
  • Shigehira Saji
  • Akiyo Yoshimura

The venues where Hiroji Iwata most often publishes include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Breast Cancer
  • Japanese Journal of Clinical Oncology

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Peter Schmid;Stephen Y Chui;Leisha A Emens

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

    Norikazu Masuda;Soo-Jung Lee;Shoichiro Ohtani;Young-Hyuck Im

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Shanu Modi;Cristina Saura;Toshinari Yamashita;Yeon Hee Park

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk

    Kyriaki Michailidou;Per Hall;Anna Gonzalez-Neira;Maya Ghoussaini

  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

    Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

    Kyriaki Michailidou;Jonathan Beesley;Sara Lindstrom;Sander Canisius

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial

    Thomas M. Suter;Marion Procter;Dirk J. van Veldhuisen;Michael Muscholl

  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

    Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley

  • Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.

    Shanu Modi;Haeseong Park;Rashmi K. Murthy;Hiroji Iwata

Frequent Co-Authors

Masakazu Toi
Masakazu Toi Kyoto University
Keitaro Matsuo
Keitaro Matsuo Nagoya University
Chen-Yang Shen
Chen-Yang Shen Academia Sinica
Yasuo Ohashi
Yasuo Ohashi Chuo University
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Kenneth W. Muir
Kenneth W. Muir University of Manchester
Roger L. Milne
Roger L. Milne Cancer Council Victoria
Daehee Kang
Daehee Kang Seoul National University
Hiltrud Brauch
Hiltrud Brauch German Cancer Research Center
Graham G. Giles
Graham G. Giles University of Melbourne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are exploring pathways related to Medicine in the USA, several online degrees can help you build or advance a healthcare career. For those interested in healthcare management, there are cahme accredited online healthcare administration programs that combine flexibility with recognized standards, preparing graduates for leadership roles.

Registered nurses who want to enhance their credentials and career options may benefit from best online rn to bsn programs without clinical requirements. These options are designed for working professionals and may offer an accelerated track with fewer in-person demands.

For nurses aiming for top clinical or leadership roles, dnp online programs offer advanced, practice-focused doctoral training. There are also online dnp programs that emphasize accessibility and flexible scheduling, making it easier for busy professionals to further their education and impact in the healthcare industry.

Best Scientists Citing Hiroji Iwata

Trending Scientists

Recently Published Articles